CN109908124A - 利用卤芬酯或卤芬酸以及第二尿酸降低剂治疗痛风患者中高尿酸血症的方法 - Google Patents

利用卤芬酯或卤芬酸以及第二尿酸降低剂治疗痛风患者中高尿酸血症的方法 Download PDF

Info

Publication number
CN109908124A
CN109908124A CN201910004813.0A CN201910004813A CN109908124A CN 109908124 A CN109908124 A CN 109908124A CN 201910004813 A CN201910004813 A CN 201910004813A CN 109908124 A CN109908124 A CN 109908124A
Authority
CN
China
Prior art keywords
uric acid
lower alkoxy
depressant
halofenate
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910004813.0A
Other languages
English (en)
Chinese (zh)
Inventor
布赖恩·K·罗伯茨
戈帕尔·钱德拉·萨哈
布赖恩·爱德华·拉万
查尔斯·A·麦克沃特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyer Tex Ltd By Share Ltd
Shellfish Pharmaceuticals Of Sigma
Original Assignee
Dyer Tex Ltd By Share Ltd
Shellfish Pharmaceuticals Of Sigma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyer Tex Ltd By Share Ltd, Shellfish Pharmaceuticals Of Sigma filed Critical Dyer Tex Ltd By Share Ltd
Priority to CN201910004813.0A priority Critical patent/CN109908124A/zh
Publication of CN109908124A publication Critical patent/CN109908124A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201910004813.0A 2011-11-04 2011-11-04 利用卤芬酯或卤芬酸以及第二尿酸降低剂治疗痛风患者中高尿酸血症的方法 Pending CN109908124A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910004813.0A CN109908124A (zh) 2011-11-04 2011-11-04 利用卤芬酯或卤芬酸以及第二尿酸降低剂治疗痛风患者中高尿酸血症的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910004813.0A CN109908124A (zh) 2011-11-04 2011-11-04 利用卤芬酯或卤芬酸以及第二尿酸降低剂治疗痛风患者中高尿酸血症的方法
PCT/US2011/059394 WO2013066349A1 (en) 2011-11-04 2011-11-04 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
CN201180076191.4A CN104066427A (zh) 2011-11-04 2011-11-04 利用卤芬酯或卤芬酸以及第二尿酸降低剂治疗痛风患者中高尿酸血症的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180076191.4A Division CN104066427A (zh) 2011-11-04 2011-11-04 利用卤芬酯或卤芬酸以及第二尿酸降低剂治疗痛风患者中高尿酸血症的方法

Publications (1)

Publication Number Publication Date
CN109908124A true CN109908124A (zh) 2019-06-21

Family

ID=48192533

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910004813.0A Pending CN109908124A (zh) 2011-11-04 2011-11-04 利用卤芬酯或卤芬酸以及第二尿酸降低剂治疗痛风患者中高尿酸血症的方法
CN201180076191.4A Pending CN104066427A (zh) 2011-11-04 2011-11-04 利用卤芬酯或卤芬酸以及第二尿酸降低剂治疗痛风患者中高尿酸血症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201180076191.4A Pending CN104066427A (zh) 2011-11-04 2011-11-04 利用卤芬酯或卤芬酸以及第二尿酸降低剂治疗痛风患者中高尿酸血症的方法

Country Status (13)

Country Link
EP (1) EP2773336A4 (enrdf_load_stackoverflow)
JP (1) JP6202633B2 (enrdf_load_stackoverflow)
KR (1) KR20140121383A (enrdf_load_stackoverflow)
CN (2) CN109908124A (enrdf_load_stackoverflow)
AU (1) AU2011380507B2 (enrdf_load_stackoverflow)
CA (1) CA2859686C (enrdf_load_stackoverflow)
CL (1) CL2014001155A1 (enrdf_load_stackoverflow)
IL (1) IL232386A0 (enrdf_load_stackoverflow)
MX (1) MX357507B (enrdf_load_stackoverflow)
NZ (1) NZ624708A (enrdf_load_stackoverflow)
SG (1) SG11201402032RA (enrdf_load_stackoverflow)
WO (1) WO2013066349A1 (enrdf_load_stackoverflow)
ZA (1) ZA201403575B (enrdf_load_stackoverflow)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104602686A (zh) * 2012-04-13 2015-05-06 西玛贝医药公司 利用卤芬酯或卤芬酸以及抗炎剂治疗痛风患者中高尿酸血症的方法
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
JP6368756B2 (ja) * 2016-10-20 2018-08-01 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
CN108014108A (zh) * 2016-11-03 2018-05-11 江苏万邦生化医药股份有限公司 lesinurad或其医药上可接受的盐在制备治疗或预防库欣综合征的药物中的应用
WO2019082335A1 (ja) * 2017-10-26 2019-05-02 大塚製薬株式会社 イノシトールリン酸含有組成物
WO2021186250A2 (en) * 2020-03-15 2021-09-23 Allen Davidoff Methods of treating viral infections and health consequences

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011032175A1 (en) * 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US9023856B2 (en) * 2011-11-04 2015-05-05 Cymabay Therapeutics, Inc. Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011032175A1 (en) * 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS.GOV: "NCT01399008", 《HTTPS://CLINICALTRIALS.GOV/CT2/HISTORY/NCT01399008?V_1=VIEW#STUDYPAGETOP》 *
CLINICALTRIALS.GOV: "NCT01416402", 《HTTPS://CLINICALTRIALS.GOV/CT2/HISTORY/NCT01416402?V_2=VIEW#STUDYPAGETOP》 *

Also Published As

Publication number Publication date
CA2859686A1 (en) 2013-05-10
CA2859686C (en) 2018-09-11
EP2773336A4 (en) 2015-06-03
JP6202633B2 (ja) 2017-09-27
MX357507B (es) 2018-07-12
WO2013066349A1 (en) 2013-05-10
AU2011380507A1 (en) 2014-05-29
EP2773336A1 (en) 2014-09-10
JP2014532758A (ja) 2014-12-08
CN104066427A (zh) 2014-09-24
IL232386A0 (en) 2014-06-30
ZA201403575B (en) 2015-11-25
SG11201402032RA (en) 2014-09-26
CL2014001155A1 (es) 2015-01-16
AU2011380507B2 (en) 2017-06-15
KR20140121383A (ko) 2014-10-15
NZ624708A (en) 2015-11-27
MX2014005400A (es) 2015-02-12

Similar Documents

Publication Publication Date Title
US10137112B2 (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
CN109908124A (zh) 利用卤芬酯或卤芬酸以及第二尿酸降低剂治疗痛风患者中高尿酸血症的方法
CN109045009A (zh) 治疗痛风急性发作的方法
AU2013245675B2 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
JP6047172B2 (ja) 患者部分集団における痛風の治療方法
JP6368756B2 (ja) ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
US20130302305A1 (en) Methods for Treating Gout in Patients Subpopulations
JP6192142B2 (ja) 痛風発赤の治療方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190621

WD01 Invention patent application deemed withdrawn after publication